Adimab, LLC has licensed its technology transfer program to Novo Nordisk and will receive upfront payments, annual licensing fees and royalties on commercialized products. Novo Nordisk has been granted a non-exclusive license to use Adimab’s antibody platform for the discovery and optimization of antibodies.   “We are pleased to have expanded our partnership with Novo Nordisk,” said Tillman Gerngross, chief executive officer and co-founder of Adimab. “This is the third platform transfer this yea...